Canaccord lowered the firm’s price target on Clene to $5.00 from $6.00 and keeps a Buy rating on the shares. The firm said its intriguing biomarker data means the next stop is with the FDA and as biomarker data could become meaningful in FDA discussions, we are tweaking our probability of approval for CNM-Au8 in ALS from 25% to 33%.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CLNN:
- Clene Welcomes New Shareholder Base and Announces Closing of Underwritten Public Offering of $40 Million
- Clene price target lowered to $7 from $15 at H.C. Wainwright
- Clene Announces Pricing of $40 Million Public Offering
- Clene 50M share Spot Secondary priced at $0.80
- Clene Announces Launch of Proposed Public Offering